Utilizza questo identificativo per citare o creare un link a questo documento: http://elea.unisa.it/xmlui/handle/10556/4486

Abstract:

We describe the case of a 69-year old male with an EGFR- positive Imatinib refractory sacral chordoma with synchronous lung metastases, treated with erlotinib, a first- generation EGFR inhibitor. After disease progression following firstline Imatinib and a combination therapy with everolimus plus metformin, we made a challenge with an EGFR tyrosine kinase inhibitor (EGFR TKI), erlotinib. Despite a brief clinical benefit, the patient presented a rapid clinical deterioration leading to death, after 8 weeks of treatment.

È visualizzato nelle collezioni:

Translational Medicine @ UniSa. Volume 16 (jen. - jun. 2017)

File in questo documento:

Non ci sono file allegati a questo documento

Visualizza tutti i metadati del documento

DSpace JSPUI

DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets